trial

Effects of Atomoxetine on Cognitive Function in Schizophrenia

NCTId NCT00420498
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 12 (actual)
Sponsored by Yale University
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-08
Primary completion
—
Eligibility
ALL · 18 Years · 59 Years

Interventions & indications

Drugs
Atomoxetine (Strattera™)

Sponsors

Yale UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Kristi A Sacco, Psy.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

3 sourced
Enrollment
12
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Atomoxetine (Strattera™)
drug
lead_sponsor
Yale University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Smoking
indication
Cigarette Smoking
indication
Cognition
indication
investigator
Kristi A Sacco, Psy.D.
person